Copy to clipboard 
Treace Medical reported 2Q25 orthopedic sales of $47.4 million, up 6.6% compared to the second quarter of 2024. For the first half of 2025, the company generated $100 million in orthopedic sales, up 4.6% compared to the prior period.
The company bolstered its Lapiplasty and Adductoplasty systems with three new bunion correction systems: Nanoplasty osteotomy, Percuplasty 3D MIS osteotomy and the SpeedMTP Great Toe Fusion system. Treace’s portfolio is now primed to address all four categories of bunions and should allow the company to drive further procedure penetration.
The most immediate growth opportunity is among Treace’s 3,100 active surgeons. The company estimates that it penetrated around 30% of their bunion cases, and can now better access the remaining 70% with its new bunion systems.
Those three new systems also give Treace access to surgeons it previously did not call upon. To complete the flywheel effect, those newly onboarded surgeons could potentially adopt Lapiplasty and Adductoplasty.
The company’s growth, along with most of the foot and ankle market, was slower in the first half of 2025. Treace expects growth to be weighted toward the second half, and especially the fourth quarter. The company reaffirmed its 2025 guidance of revenues in the range between $224 million and $230 million, representing growth of 7% to 10% over 2024.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Trauma | $47.4 | $44.5 | $2.9 | 6.6% |
| Segment | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| Trauma | $100.0 | $95.6 | $4.4 | 4.6% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $47.4 | |
| Cost of Sales | $9.6 | 20.3% |
| Sales and Marketing | $33.1 | 69.8% |
| General and Admin | $16.1 | 34.1% |
| R & D | $5.5 | 11.6% |
| Other | $0.4 | 0.9% |
| Net Earnings | ($17.4) | (36.7%) |
Treace Medical reported 2Q25 orthopedic sales of $47.4 million, up 6.6% compared to the second quarter of 2024. For the first half of 2025, the company generated $100 million in orthopedic sales, up 4.6% compared to the prior period.
The company bolstered its Lapiplasty and Adductoplasty systems with three new bunion correction systems:...
Treace Medical reported 2Q25 orthopedic sales of $47.4 million, up 6.6% compared to the second quarter of 2024. For the first half of 2025, the company generated $100 million in orthopedic sales, up 4.6% compared to the prior period.
The company bolstered its Lapiplasty and Adductoplasty systems with three new bunion correction systems: Nanoplasty osteotomy, Percuplasty 3D MIS osteotomy and the SpeedMTP Great Toe Fusion system. Treace’s portfolio is now primed to address all four categories of bunions and should allow the company to drive further procedure penetration.
The most immediate growth opportunity is among Treace’s 3,100 active surgeons. The company estimates that it penetrated around 30% of their bunion cases, and can now better access the remaining 70% with its new bunion systems.
Those three new systems also give Treace access to surgeons it previously did not call upon. To complete the flywheel effect, those newly onboarded surgeons could potentially adopt Lapiplasty and Adductoplasty.
The company’s growth, along with most of the foot and ankle market, was slower in the first half of 2025. Treace expects growth to be weighted toward the second half, and especially the fourth quarter. The company reaffirmed its 2025 guidance of revenues in the range between $224 million and $230 million, representing growth of 7% to 10% over 2024.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Trauma | $47.4 | $44.5 | $2.9 | 6.6% |
| Segment | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| Trauma | $100.0 | $95.6 | $4.4 | 4.6% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $47.4 | |
| Cost of Sales | $9.6 | 20.3% |
| Sales and Marketing | $33.1 | 69.8% |
| General and Admin | $16.1 | 34.1% |
| R & D | $5.5 | 11.6% |
| Other | $0.4 | 0.9% |
| Net Earnings | ($17.4) | (36.7%) |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
